Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Not Yet Opened 08-24 16:00:00 EDT

19.27

-0.56

-2.82%

盘后19.27

+0.000.00%

19:30 EDT

High19.86	Low18.88	Vol759.04K
Open19.86	D1 Closing19.83	Amplitude4.94%
Mkt Cap1.03B	Tradable Cap773.68M	Total Shares53.63M
T/O14.70M	T/O Rate1.89%	Tradable Shares40.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":19.27,"timestamp":1787601600000,"preClose":19.83,"halted":0,"volume":759039,"hourTrading":{"tag":"盘后","latestPrice":19.27,"preClose":19.27,"latestTime":"19:30 EDT","volume":2541,"amount":48964.78,"timestamp":1787614203422,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.028240040342914715,"floatShares":40149500,"shares":53630000,"eps":-4.41,"marketStatus":"Not Yet Opened","change":-0.56,"latestTime":"08-24 16:00:00 EDT","open":19.86,"high":19.86,"low":18.88,"amount":14701120.48473,"amplitude":0.04942,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.41,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":19.83,"preHourTrading":{"tag":"盘前","latestPrice":19.73,"preClose":19.83,"latestTime":"09:14 EDT","volume":16,"amount":315.484992,"timestamp":1787577242845,"change":-0.1,"changeRate":-0.005043,"amplitude":0.000656},"postHourTrading":{"tag":"盘后","latestPrice":19.27,"preClose":19.27,"latestTime":"19:30 EDT","volume":2541,"amount":48964.78,"timestamp":1787614203422,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.952735,"impliedVol":0.8765,"impliedVolPercentile":0.404},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"2660478020","title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of Common Shares Worth $1.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478020","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478020?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:11","pubTimestamp":1787170261,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of common shares worth $1.44 millionAvalo Therapeutics CFO Christopher Ryan Sullivan exercised stock options on Aug. 17-18 at USD 9.88.He sold","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLbGHJFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of Common Shares Worth $1.44 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490852","title":"Is Avalo Therapeutics (AVTX) Cheap As Wider Q2 Losses Meet A Lower P B?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490852?lang=en_us&edition=fundamental","pubTime":"2026-08-19 05:30","pubTimestamp":1787088626,"startTime":"0","endTime":"0","summary":"Q2 earnings highlight a wider net loss but improved per share figures\nAvalo Therapeutics (AVTX) reported second quarter and first half 2026 results, with higher net losses than a year earlier. Loss per share figures improved, which gives investors a mixed picture to assess.\nSee our latest analysis for Avalo Therapeutics.\nAvalo Therapeutics shares trade at US$19.71 after a recent 20.99% 90 day share price return and a 121.59% 1 year total shareholder return, although the 5 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/is-avalo-therapeutics-avtx-cheap-as-wider-q2-losses-meet-a-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/is-avalo-therapeutics-avtx-cheap-as-wider-q2-losses-meet-a-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659090083","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 679 Common Shares Worth $13,580","url":"https://stock-news.laohu8.com/highlight/detail?id=2659090083","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659090083?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:11","pubTimestamp":1786565465,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of 679 common shares worth $13,580Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 679 shares on Aug. 10 at USD 20.Sale followed an option exerci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6lxWWc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 679 Common Shares Worth $13,580","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657580536","title":"Avalo Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657580536","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657580536?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:05","pubTimestamp":1786028751,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAvalo Therapeutics IncAVTX.OQreported a quarterly adjusted loss of 83 cents per share for the quarter ended June ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063925","title":"CG Oncology Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063925","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063925?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:22","pubTimestamp":1786018956,"startTime":"0","endTime":"0","summary":"CG Oncology Q2 net loss widens on higher R&D costsOverviewUS biopharmaceutical firm's Q2 rev rose to $1.2 mln, reflecting early commercialization activityNet loss widened to $79.1 mln, driven by highe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CHRS","CMPX","BK4535","AVTX","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763962","title":"Avalo Q2 2026 Earnings: $472.2 Million Supports 2027 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763962","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763962?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:56","pubTimestamp":1786017369,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics reported a Q2 2026 net loss of $36.4 million, widening from $20.8 million, while diluted loss per share narrowed to $0.83 from $1.92 because weighted average shares increased sharply. R&D expense rose to $23.4 million, including a $10.0 million abdakibart milestone, and cash, equivalents and investments totaled $472.2 million at June 30. Management expects that balance to fund operations into 2029 as Avalo targets an abdakibart Phase 3 start and an AVTX-010 IND submission in the first half of 2027.","market":"sh","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock9.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock9.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262083419-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633927","title":"Avalo Therapeutics Posts Corporate Deck Spotlighting IL-1β Inhibitor Pipeline for Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633927","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633927?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:26","pubTimestamp":1786015603,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics posts corporate deck spotlighting IL-1β inhibitor pipeline for hidradenitis suppurativaAvalo outlined an IL-1β inhibitor strategy for immune-mediated inflammatory diseases, led by a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9myvwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638018","title":"Avalo Q2 FY26 Net Loss Widens to $36.4 Million; R&D Expense Rises 66.1% to $23.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638018","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638018?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:15","pubTimestamp":1786014924,"startTime":"0","endTime":"0","summary":"Avalo Q2 FY26 net loss widens to $36.4 million; R&D expense rises 66.1% to $23.4 millionAvalo Therapeutics posted a Q2 net loss of $36.4 million, widening from $20.8 million a year earlier.R&D expense","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL4bPT83:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680722","title":"Press Release: Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680722?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"-- Plans to initiate a registrational Phase 3 program evaluating abdakibart. in hidradenitis suppurativa  in the first half of 2027. -- Expanded pipeline with AVTX-010, a long-acting next-generation. anti-IL-1<BETA> antibody, with IND submission planned for the first half. -- Cash, cash equivalents and investments of $472.2 million as of June 30,abdakibart in HS in the first half of 2027.HS as well as other inflammatory disorders. The Company expects to submit. an Investigational New Drug  application in the first half of 2027.-- Appointed Ron Philip to its Board of Directors. Ron contributes deep. strategic and commercial expertise, with a proven track record of. -- Added to the Russell 2000 and Russell 3000 Indexes as part of the. 2026. Net cash used in operating activities was $37.7 million for the six. months ended June 30, 2026. Avalo's current cash, cash equivalents, and. investments are expected to fund operations into 2029.-- Research and development expenses were $23.4 million","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","LENZ","BK4022","BK4139","IND","BK4539","R","BK4007","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656371291","title":"Avalo Therapeutics Inc Expected to Post a Loss of 58 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656371291","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656371291?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:05","pubTimestamp":1785762308,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc <AVTX.OQ> expected to post a loss of58cents a share - Earnings PreviewAvalo Therapeutics IncAVTX.OQAVTX.Ois expected to  show no change in quarterly revenue when it reports  res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4401D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816802","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of Common Shares Worth $20,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816802","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816802?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:06","pubTimestamp":1785355610,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of common shares worth $20,000Avalo Therapeutics Chief Medical Officer Doyle Mittie exercised stock options for 1,000 shares at USD 12.65 on July 27, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL8yFfN3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of Common Shares Worth $20,000","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655400838","title":"Avalo Therapeutics - Selling Stockholders May Sell up to 128,189 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655400838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655400838?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:44","pubTimestamp":1785271465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1FI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652800552","title":"Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2652800552","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652800552?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:22","pubTimestamp":1784319732,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) on Friday filed a registration statement with the US Securities and Exchange Commission saying that some shareholders may from time to time sell up to 128,189 of its shares.The company said it will not receive any proceeds from the proposed sale.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652572238","title":"Avalo Therapeutics files to sell 128,189 shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2652572238","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652572238?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:05","pubTimestamp":1784318711,"startTime":"0","endTime":"0","summary":"16:04 EDT Avalo Therapeutics (AVTX) files to sell 128,189 shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-files-to-sell-128189-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-files-to-sell-128189-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649300959","title":"What Avalo Therapeutics (AVTX)'s Russell Index Additions and Board Refresh Mean for Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2649300959","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649300959?lang=en_us&edition=fundamental","pubTime":"2026-07-08 03:48","pubTimestamp":1783453685,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics was recently added to multiple Russell indices and appointed veteran biopharma executive Ron Philip to its board, moves that follow positive Phase 2 data for its lead IL‑1β antibody abdakibart in hidradenitis suppurativa and preparation for investor meetings at the Leerink Partners Therapeutics Forum.\nTogether, the index inclusions, strengthened governance, and focus on IL‑1β‑targeted therapies highlight how a once‑smaller biotech is gaining broader institutional...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/what-avalo-therapeutics-avtxs-russell-index-additions-and-bo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avtx/avalo-therapeutics/news/what-avalo-therapeutics-avtxs-russell-index-additions-and-bo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624485","title":"U.S. Stocks on the Move-core Natural Resources, Grabagun, Terawulf","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624485?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:09","pubTimestamp":1783343380,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Core Natural Resources, GrabAGun, TeraWulfWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL6N4380KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","BK4156","WULF","ESI","IE0031619046.USD","BK4023","S","BK4200","GD","AVTX","FOWF","BK4539","BK4561","CLVT","LU0823417653.USD","LU0950375773.USD","SHLD","FDIG","XES","BK4600","CNR","IE00BN0W2V16.EUR","LU1043141396.HKD","LU0823417737.USD","BK4585","PSCM","BK4588","LU0426412945.USD","LU2506952097.USD","IE00BN0W2T93.GBP","BK4595","COAL","LU2506951958.HKD","SG9999015978.USD","SEI","BK4123","LU0994945656.USD","SOLS","PEW","LU0426417589.USD","OIH","WULX","BK4560","CHKP","PPA","LU0170899867.USD","BK4139","LU2506952170.USD","LU1043141123.HKD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624621","title":"Leerink Starts Avalo at \"outperform\" on Skin Disease Drug Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624621?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:19","pubTimestamp":1783340391,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink starts Avalo at \"outperform\" on skin disease drug potential** Shares of drug developer Avalo TherapeuticsAVTX.Orise 2.9% to $19.40 premarket** Leerink Partners initiates coverage of AVTX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4N4380QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0211328371.USD","AVTX","IXJ","LU0310800379.SGD","IE00BDGV0183.EUR","LU0256863811.USD","FTXH","VHT","RXL","LU0511384066.AUD","PJP","LU0689472784.USD","LU2129689605.HKD","LU0234570918.USD","LU2087621335.USD","LU2347655156.SGD","IE00BGHQF631.EUR","LU0203347892.USD","BK4588","IE000WAW04H5.SGD","LU1037948541.HKD","PPH","LU0124676726.USD","LU0098860793.USD","LU0882574055.USD","IE00B3PB1722.GBP","LU0289739343.SGD","LU1267930573.SGD","LU1057294990.SGD","LU2089984988.USD","LU2237443978.SGD","AGNG","LU0058720904.USD","XLV","LU0122379950.USD","JDOC","MEDX","ABBV","FHLC","IYH","LU1934455277.USD","LU0114720955.EUR","LU2089284900.SGD","LU2129689514.USD","BK4139","SG9999001440.SGD","IE00B19Z3B42.SGD","LU1670627923.USD","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649366625","title":"Avalo Therapeutics Inc : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2649366625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649366625?lang=en_us&edition=fundamental","pubTime":"2026-07-06 18:52","pubTimestamp":1783335176,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648384906","title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 4,654 Common Shares Valued at $93,080","url":"https://stock-news.laohu8.com/highlight/detail?id=2648384906","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648384906?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:07","pubTimestamp":1783022820,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CMO Mittie Doyle disposes of 4,654 common shares valued at $93,080Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises on June 30, 2026, acquiring 4,654 c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL2ZkMFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo Therapeutics CMO Mittie Doyle Disposes of 4,654 Common Shares Valued at $93,080","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646351820","title":"Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646351820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646351820?lang=en_us&edition=fundamental","pubTime":"2026-06-26 19:00","pubTimestamp":1782471612,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42X0Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.0341},{"period":"1month","weight":0.045},{"period":"3month","weight":0.2029},{"period":"6month","weight":0.1433},{"period":"1year","weight":0.9504},{"period":"ytd","weight":0.0611}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.088879},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.046144},{"month":6,"riseRate":0.727273,"avgChangeRate":0.024954},{"month":7,"riseRate":0.454545,"avgChangeRate":0.02164},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.026379},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}